These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1750016)

  • 1. Prophylactic intranasal alpha 2 interferon and viral exacerbations of chronic respiratory disease.
    Wiselka MJ; Nicholson KG; Kent J; Cookson JB; Tyrrell DA
    Thorax; 1991 Oct; 46(10):706-11. PubMed ID: 1750016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic efficacy and tolerance of low-dose intranasal interferon-alpha 2 in natural respiratory viral infections.
    Hayden FG; Gwaltney JM; Johns ME
    Antiviral Res; 1985 Apr; 5(2):111-6. PubMed ID: 4015079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of respiratory virus infection in patients with chronic chest disease.
    Wiselka MJ; Kent J; Cookson JB; Nicholson KG
    Epidemiol Infect; 1993 Oct; 111(2):337-46. PubMed ID: 8405160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic efficacy of intranasal alpha 2-interferon against rhinovirus infections in the family setting.
    Douglas RM; Moore BW; Miles HB; Davies LM; Graham NM; Ryan P; Worswick DA; Albrecht JK
    N Engl J Med; 1986 Jan; 314(2):65-70. PubMed ID: 3001518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal interferon-alpha 2 prophylaxis of natural respiratory virus infection.
    Douglas RM; Albrecht JK; Miles HB; Moore BW; Read R; Worswick DA; Woodward AJ
    J Infect Dis; 1985 Apr; 151(4):731-6. PubMed ID: 2982972
    [No Abstract]   [Full Text] [Related]  

  • 6. Intranasal interferon-alpha 2b for seasonal prophylaxis of respiratory infection.
    Monto AS; Shope TC; Schwartz SA; Albrecht JK
    J Infect Dis; 1986 Jul; 154(1):128-33. PubMed ID: 3011917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study of intranasally administered interferon A (rIFN-alpha 2A) for the seasonal prophylaxis of natural viral infections of the upper respiratory tract in healthy volunteers.
    Tannock GA; Gillett SM; Gillett RS; Barry RD; Hensley MJ; Herd R; Reid AL; Saunders NA
    Epidemiol Infect; 1988 Dec; 101(3):611-21. PubMed ID: 3215290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal recombinant alfa-2b interferon treatment of naturally occurring common colds.
    Hayden FG; Kaiser DL; Albrecht JK
    Antimicrob Agents Chemother; 1988 Feb; 32(2):224-30. PubMed ID: 2834996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal interferon-alpha 2 for prevention of natural rhinovirus colds.
    Farr BM; Gwaltney JM; Adams KF; Hayden FG
    Antimicrob Agents Chemother; 1984 Jul; 26(1):31-4. PubMed ID: 6089652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral respiratory tract infection and exacerbations of asthma in adult patients.
    Beasley R; Coleman ED; Hermon Y; Holst PE; O'Donnell TV; Tobias M
    Thorax; 1988 Sep; 43(9):679-83. PubMed ID: 3194873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal interferon alpha 2 for prevention of rhinovirus infection and illness.
    Hayden FG; Gwaltney JM
    J Infect Dis; 1983 Sep; 148(3):543-50. PubMed ID: 6311914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal tolerance and histopathologic effects of a novel synthetic interferon, rIFN-alpha Con1.
    Hayden FG; Innes DJ; Mills SE; Levine PA
    Antiviral Res; 1988 Dec; 10(4-5):225-34. PubMed ID: 2852485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal interferon (rIFN-alpha A, Ro 22-8181) for contact prophylaxis against common cold: a randomized, double-blind and placebo-controlled field study.
    Herzog C; Berger R; Fernex M; Friesecke K; Havas L; Just M; Dubach UC
    Antiviral Res; 1986 May; 6(3):171-6. PubMed ID: 3524441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon.
    Hayden FG; Albrecht JK; Kaiser DL; Gwaltney JM
    N Engl J Med; 1986 Jan; 314(2):71-5. PubMed ID: 3001519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Demonstration of dose-response relationship in seasonal prophylaxis of respiratory infections with alpha-2b interferon.
    Monto AS; Albrecht JK; Schwartz SA
    Antimicrob Agents Chemother; 1988 Jan; 32(1):47-50. PubMed ID: 2831814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of experimental coronavirus colds with intranasal alpha-2b interferon.
    Turner RB; Felton A; Kosak K; Kelsey DK; Meschievitz CK
    J Infect Dis; 1986 Sep; 154(3):443-7. PubMed ID: 3016111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A field trial of recombinant human interferon alpha-2b for nasal spray to prevent SARS and other respiratory viral infections].
    Yu DX; Chen Q; Zhang LL; Liu Y; Yu ZA; Li ZF; Zhang LP; Hu GF; Duan ZJ; Chu XW; Zhang B; Yu SY; Hou YD
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2005 Sep; 19(3):216-9. PubMed ID: 16261200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in symptoms, peak expiratory flow, and sputum flora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice.
    Sachs AP; Koëter GH; Groenier KH; van der Waaij D; Schiphuis J; Meyboom-de Jong B
    Thorax; 1995 Jul; 50(7):758-63. PubMed ID: 7570411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infective factors in exacerbations of bronchitis and asthma.
    Lambert HP; Stern H
    Br Med J; 1972 Aug; 3(5822):323-7. PubMed ID: 4403011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers.
    Higgins PG; Phillpotts RJ; Scott GM; Wallace J; Bernhardt LL; Tyrrell DA
    Antimicrob Agents Chemother; 1983 Nov; 24(5):713-5. PubMed ID: 6318655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.